Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19000980 | 1.00 | ALDH1A1 (0.42) | ALDH1A1HTTLMNAHSD11B1TRPV1 | |
| SCHEMBL25675662 | 0.84 | HTT (0.48) | ALDH1A1HTTLMNAHSD11B1TRPV1 | |
| SCHEMBL19001117 | 0.84 | ALDH1A1 (0.35) | ALDH1A1LMNAHSD11B1TRPV1RECQL | |
| SCHEMBL19001017 | 0.84 | ALDH1A1 (0.35) | ALDH1A1LMNAHSD11B1TRPV1RECQL | |
| SCHEMBL19012687 | 0.83 | KMT2A (0.43) | ALDH1A1HTTLMNATRPV1KDM4E | |
| SCHEMBL19012392 | 0.83 | KMT2A (0.43) | ALDH1A1HTTLMNATRPV1KDM4E | |
| SCHEMBL25675666 | 0.83 | RECQL (0.39) | ALDH1A1HTTLMNAHSD11B1TRPV1 | |
| SCHEMBL19001085 | 0.81 | ALDH1A1 (0.34) | ALDH1A1HTTLMNAHSD11B1POLB | |
| SCHEMBL19001008 | 0.81 | ALDH1A1 (0.34) | ALDH1A1HTTLMNAHSD11B1POLB | |
| SCHEMBL19000961 | 0.81 | GAA (0.35) | ALDH1A1HTTLMNAHSD11B1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | ALDH1A1 892/4885HTT 1275/4885LMNA 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.